Valens Announces Revenue Guidance for Fourth Quarter 2019

Valens announces Q4 2019 revenue guidance of $27 million – $30 million, a near doubling of Q3, 2019 reported revenue.

Valens GroWorks Corp, a cannabinoid-based product company with industry-leading extraction, next-generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, is pleased to announce revenue guidance for the recently completed fourth quarter 2019 in the range of $27 million to $30 million as well as its intention to commence a NCIB for the purchase and cancellation of up to 6,275,204 of its common shares (the "Shares") or 5% of the issued and outstanding Shares as calculated on a non-diluted basis. The NCIB will be funded with cash on hand and the Company's current positive cash flow from operations.

Revenue Guidance for Fourth Quarter 2019

The Company is pleased to announce revenue guidance for the recently completed fourth quarter of 2019 in the range of $27 million – $30 million, a significant increase over its third quarter 2019 revenue of $16.5 million.

The Company also expects to report that it has extracted over 24,400 kilograms of cannabis and hemp biomass in the fourth quarter of 2019.

This is roughly in-line with the amount of biomass processed in Q3 2019 and reflects the anticipated shift in focus to white label manufacturing and the demand from our customers to launch a breadth of "Cannabis 2.0" products into the market.

This breadth of products translated into smaller lot sizes and resulted in a temporary pause from the volume ramp seen in previous quarters but also resulted in a significant increase in our revenue per gram of input performance.

Looking forward, Valens expects to see a return to an aggressive volume growth through its facilities as large amounts of hemp biomass are brought in from the fields and customers require the large production runs that are typical in such a fast-growing market.

"I couldn't be more thrilled to share revenue guidance for Valens' fourth quarter, which I believe is only starting to show the power of our platform"

Tyler Robson, CEO of Valens.

"The reason we have built five different types of extraction in house is so that we can facilitate being a one stop shop for our customers by having the means to produce a large variety of next generation white label products. This quarter shows the flexibility of our operations and represents an inflection point in our acceleration into "Cannabis 2.0″ oil-based products. Through the incredible demand we are seeing, we expect white label sales to continue to ramp up as we increase the number of white label contracts and volume of the contracts themselves."

Intention to Launch Normal Course Issuer Bid

The Company intends to launch a NCIB for the purchase and cancellation of up to 6,275,204 Shares, representing approximately 5.0% of the issued and outstanding Shares, calculated on a non-diluted basis.  The NCIB is expected to run for a period of one year from when it is formally commenced.

The Company believes that given its strong financial and operational performance, prevailing market conditions and the price performance of its Shares, the NCIB is a prudent and appropriate approach to maximize shareholder value.

Having a NCIB in place will provide the Company with the flexibility to purchase Shares, from time to time, at the Company's discretion, as part of its capital management strategy, subject to applicable black-out periods and trading restrictions. The NCIB will be funded with cash on hand and the Company's current positive cash flow from operations.

The NCIB will be made in accordance with the applicable rules and policies of the TSXV and applicable Canadian securities laws.  Under the NCIB, the Shares may be repurchased in open market transactions on the TSXV and/or other Canadian exchanges, or by such other means as may be permitted by the TSXV and applicable Canadian securities laws.

The NCIB has been approved by the Company's board of directors but remains subject to approval by the TSXV.

Disclaimer: Past performance is not an indicator of future performance.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Niki Mohazeb
Niki Mohazeb

Niki is a Sydney based writer, with a passion for promoting the health benefits of medicinal cannabis. Niki also enjoys researching and writing about the future of cannabis along with the many other benefits that the plant provides, such as the diverse utilities of hemp.

Leave a Reply

Your email address will not be published. Required fields are marked *